Text Size

Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models

Akaishi T., Shimazaki A., Tonouchi A., Ueda K., Miyawaki N., Kawazu K.


  • 2015
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Research and Development Division, Santen Pharmaceutical Co., Ltd., 4-20 Ofukacho, Kita-ku, Osaka 530-8552, Japan

Related Publications

Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma

Kashiwagi K., Nakano T., Nakazawa T., Fuwa M., Otsuka N., Shii D., Miyahara R.


Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF


Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022